ROBERT A SOSLOW, MD
Medical Practice at York Ave, New York, NY
License number
New York 199363
Category
Medical Practice
Type
Anatomic Pathology
Address
Address
1275 York Ave, New York, NY 10021
Phone
(212) 639-2000
Personal information
See more information about ROBERT A SOSLOW at radaris.comName
Address
Phone
108 5Th Ave APT 4B, New York, NY 10011
504 E 63Rd St APT 33L, New York, NY 10065
New York, NY
108 5Th Ave, New York, NY 10011
108 5Th St, New York, NY 10011
Organization information
See more information about ROBERT A SOSLOW at bizstanding.comRobert Soslow MD
1275 York Ave, New York, NY 10065
Phone:
(800) 525-2225 (Phone)
Description:
There are 32 doctors at this site. Surgery is not performed at this site.
Robert A A Soslow
Professional information
Dr. Robert A Soslow, New York NY - MD (Doctor of Medicine)
Specialties:
Anatomic Pathology
Address:
Memorial Pulmonary Function Group
1275 York Ave SUITE H1307, New York 10065
(212) 639-6450 (Phone)
1275 York Ave SUITE H1307, New York 10065
(212) 639-6450 (Phone)
Certifications:
Anatomic Pathology, 1995
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Memorial Pulmonary Function Group
1275 York Ave SUITE H1307, New York 10065
Memorial Sloan - Kettering Cancer Center
1275 York Ave, New York 10065
1275 York Ave SUITE H1307, New York 10065
Memorial Sloan - Kettering Cancer Center
1275 York Ave, New York 10065
Education:
Medical School
University Of Pennsylvania School Of Medicine
Graduated: 1991
Stanford University Hospital
Stanford University Mc
Graduated: 1995
University Of Pennsylvania School Of Medicine
Graduated: 1991
Stanford University Hospital
Stanford University Mc
Graduated: 1995
Robert Soslow, New York NY
Specialties:
Pathology, Anatomic Pathology, Anatomic Pathology & Clinical Pathology
Work:
Memorial Sloan-Kettering
1275 York Ave, New York, NY 10065
1275 York Ave, New York, NY 10065
Education:
University of Pennsylvania(1991)
Professor At Mskcc
Location:
Greater New York City Area
Industry:
Hospital & Health Care
Experience:
MSKCC (Non-Profit; 5001-10,000 employees; Hospital & Health Care industry): Professor, (-)
Methods For Diagnosis And Treatment Of Endometrial Cancer
US Patent:
2010019, Aug 5, 2010
Filed:
Feb 28, 2006
Appl. No.:
11/884806
Inventors:
Jonathan Braun - Tarzana CA, US
Madhuri Wadehra - Fontana CA, US
Sathima Natarajan - Los Angeles CA, US
Robert Soslow - New York NY, US
Madhuri Wadehra - Fontana CA, US
Sathima Natarajan - Los Angeles CA, US
Robert Soslow - New York NY, US
International Classification:
A61K 33/24, C12Q 1/68, G01N 33/53, A61K 31/4355, A61K 31/56, A61K 31/7088, A61P 35/00
US Classification:
424649, 435 6, 435 71, 435 792, 514280, 514171, 514 44 R, 514364, 514383, 435 723, 514362, 514363
Abstract:
The present invention discloses methods of using endothelial membrane protein 2 (EMP2) as a biomarker for stratification of endometrial premalignancy, diagnosing, staging and imaging of endometrial neoplasia. Further, methods for identifying pharmaceutical/therapeutic modalities are described, including compositions which modulate glycolipid-enriched lipid raft microdomains (GEMs).
Methods For Diagnosis And Treatment Of Endometrial Cancer
US Patent:
2012026, Oct 18, 2012
Filed:
Dec 28, 2011
Appl. No.:
13/339247
Inventors:
Jonathan Braun - Tarzana CA, US
Madhuri Wadehra - Fontana CA, US
Sathima Natarajan - Los Angeles CA, US
Robert Soslow - New York NY, US
Madhuri Wadehra - Fontana CA, US
Sathima Natarajan - Los Angeles CA, US
Robert Soslow - New York NY, US
Assignee:
Memorial Sloan Kettering Cancer Center - New York NY
The Regents of the University of California - Oakland CA
The Regents of the University of California - Oakland CA
International Classification:
G01N 33/574, G01N 27/447, C40B 20/04, G01N 21/64, C12Q 1/68, C40B 30/04
US Classification:
506 4, 435 792, 435 612, 506 9, 435 611, 436501, 435 723, 204456
Abstract:
The present invention discloses methods of using endothelial membrane protein 2 (EMP2) as a biomarker for stratification of endometrial premalignancy, diagnosing, staging and imaging of endometrial neoplasia. Further, methods for identifying pharmaceutical/therapeutic modalities are described, including compositions which modulate glycolipid-enriched lipid raft microdomains (GEMs).